Seynaeve M

Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

10 papers · 1 preprint · ORCID

ArticlePsilocybin

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.

Rucker JJ, Mantingh T, Kerr-Gaffney J +26

Europe PMC2026

ArticleDMT

Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.

Seynaeve M, Dunbar F, Ermakova AO +4

Europe PMC2026

ArticleDMT

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.

Seynaeve M, Dunbar F, Hindocha C +4

Europe PMC2026

ArticleDMT

Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.

Tabaac BJ, Shinozuka K, Weisman A +3

Europe PMC2026

ArticleDMT

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depression.

Roberts C, Seynaeve M, Ermakova AO +5

Europe PMC2026

ArticleDMT

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

Marsden J, Kelleher M, Dunbar F +8

Europe PMC2025

ArticleDMT

Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.

Ermakova AO, Dunbar F, Seynaeve M +1

Europe PMC2025

PreprintDMT

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Tabaac BJ, Shinozuka K, Weisman A +3

Europe PMC2025

ArticlePsilocybin

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.

Rucker J, Butler M, Hambleton S +8

Europe PMC2024

ArticleDMT

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants.

Rucker JJ, Roberts C, Seynaeve M +6

Europe PMC2024

ArticlePsilocybin

Psychedelic treatment of functional neurological disorder: a systematic review.

Butler M, Seynaeve M, Nicholson TR +5

Europe PMC2020

Seynaeve M

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.

Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.

Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-&lt;i&gt;N,N&lt;/i&gt;-dimethyltryptamine) in patients with treatment-resistant depression.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-&lt;i&gt;N,N&lt;/i&gt;-dimethyltryptamine benzoate) in healthy participants.

Psychedelic treatment of functional neurological disorder: a systematic review.

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depression.

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants.